Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ: BOLT · USD

$6.55

+0.18 (+2.8%)· Recorded snapshot

Market cap	12.6M
Shares out	1.9M
Volume	73,286
Beta	1.01

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Market cap: 12.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

S&P 500+0.8%

Nasdaq Composite-1.0%

Dow Jones Industrial Average+1.9%

Russell 2000+0.3%

All BOLT indicators

Market & fundamental data

Available fields

147

Groups with data

Currency

USD

Showing 147 of 147 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001641281
Company name	Bolt Biotherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	097702203
Earnings date	2026-11-11
Earnings time	amc
Employees	23
Employees change	-29
Employees growth	-55.77%
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
Industry	Biotechnology
IPO date	2021-02-05
Is primary listing	Yes
Is SPAC	No
ISIN number	US0977022039
Last 10-K release date	2026-03-12
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split date	2025-06-09
Last stock split type	Reverse
Market cap	$12.6M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	No
Price	$6.55
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	BOLT
U.S. state	California
Website	https://www.boltbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
FCF yield	-257%
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROA (5Y)	-27.79%
ROE (5Y)	-63.21%
SBC / revenue	54.15%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	5
Net income growth quarters	5
Net income growth years	4
Revenue growth	12.79%
Revenue growth (Q)	-99.72%
Revenue growth (QoQ)	-80.77%
Revenue growth 3Y	-11.51%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-85,000
Depreciation and amortization	$919,000
FCF per share	$-16.37
Financing cash flow	$30,000
Free cash flow	$-31.5M
Free cash flow minus SBC	$-34.1M
Investing cash flow	$34.7M
Net cash flow	$3.2M
Operating cash flow minus SBC	$-34M
Stock-based compensation	$2.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Piotroski F-Score	0
Property, plant and equipment	$17.6M
WACC	9.79%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$20.6M
Current liabilities	$7.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	8.42%
Dividend yield	0%
Shareholder yield	8.42%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.25
1D price change	2.83%
1M price change	82.96%
1M total return	82.96%
1W price change	63.75%
1W total return	63.75%
1Y price change	9.17%
1Y return CAGR	9.17%
1Y total return	9.17%
20-day SMA	$4.15
200-day SMA	$4.50
3M price change	71.02%
3M total return	71.02%
3Y price change	-65.89%
3Y return CAGR	-30.12%
3Y total return	-65.89%
50-day SMA	$3.88
50-day SMA vs 200-day SMA	50under200
52-week high	$7.78
52-week high date	2026-10-23
52-week low	$3.10
52-week low date	2026-09-18
5Y price change	-97.47%
5Y return CAGR	-52.08%
5Y total return	-97.47%
6M price change	35.61%
6M total return	35.61%
All-time high	$861.40
All-time high date	2021-03-11
All-time low	$3.10
All-time low date	2026-09-18
Average true range (ATR)	$0.59
Average volume	685.5K
Beta (1Y)	0.37
Beta (2Y)	0.38
Beta (5Y)	1.01
Change from 52-week high	-15.81%
Change from 52-week low	111.29%
Change from all-time high	-99.24%
Change from all-time low	111.29%
Change from open	3.31%
Day's gap	-0.47%
Dollar volume	$480,023
High price	$6.55
Low price	$6.34
Monthly RSI	33.74
Open price	$6.34
Position in 52-week range	100%
Premarket change	0.31%
Premarket close	$6.37
Premarket price	$6.39
Premarket volume	1.3K
Previous close	$6.37
Price vs 150-day SMA	54.23%
Price vs 20-day SMA	58.02%
Price vs 200-day SMA	45.62%
Price vs 50-day SMA	69.03%
Relative volume	0.11
Return from IPO open	-98.78%
Return from IPO price	-68.15%
RSI	81.35
Sharpe ratio	0.52
Sharpe ratio (3Y)	-0.2
Sharpe ratio (5Y)	-0.58
Sortino ratio	0.99
Sortino ratio (3Y)	-0.22
Sortino ratio (5Y)	-0.74
Volume	73.3K
Weekly RSI	68.74
YTD price change	19.79%
YTD total return	19.79%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Shares change (QoQ)	0.6%
Shares change (YoY)	-8.42%
Shares outstanding	1.9M
Short % of shares	1.34%
Short ratio	0.7 days

Deeper analysis on BOLT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BOLT report

Is a complete BOLT research report available?

No complete published report is available for Bolt Biotherapeutics, Inc. (BOLT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Bolt Biotherapeutics, Inc. (BOLT)

Price

Financial snapshot

Fair-value bridge

Latest news · BOLT

Valuation

Trading

Next earnings

Sector percentile context

All BOLT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BOLT

Frequently asked questions